Pellegrini Joaquin Miguel, Gorvel Jean-Pierre, Mémet Sylvie
Centre d'Immunologie de Marseille Luminy, INSERM, CNRS, Aix-Marseille Université, Parc Scientifique et Technologique de Luminy, Case 906, CEDEX 09, 13288 Marseille, France.
Microorganisms. 2022 Jun 21;10(7):1260. doi: 10.3390/microorganisms10071260.
Brucellosis is considered one of the major zoonoses worldwide, constituting a critical livestock and human health concern with a huge socio-economic burden. genus, its etiologic agent, is composed of intracellular bacteria that have evolved a prodigious ability to elude and shape host immunity to establish chronic infection. 's intracellular lifestyle and pathogen-associated molecular patterns, such as its specific lipopolysaccharide (LPS), are key factors for hiding and hampering recognition by the immune system. Here, we will review the current knowledge of evading and immunosuppressive mechanisms elicited by species to persist stealthily in their hosts, such as those triggered by their LPS and cyclic β-1,2-d-glucan or involved in neutrophil and monocyte avoidance, antigen presentation impairment, the modulation of T cell responses and immunometabolism. Attractive strategies exploited by other successful chronic pathogenic bacteria, including , , and , will be also discussed, with a special emphasis on the mechanisms operating in brucellosis, such as granuloma formation, pyroptosis, and manipulation of type I and III IFNs, B cells, innate lymphoid cells, and host lipids. A better understanding of these stratagems is essential to fighting bacterial chronic infections and designing innovative treatments and vaccines.
布鲁氏菌病被认为是全球主要的人畜共患病之一,对家畜和人类健康构成重大威胁,并带来巨大的社会经济负担。其病原体布鲁氏菌属由细胞内细菌组成,这些细菌进化出了强大的能力来逃避和塑造宿主免疫以建立慢性感染。布鲁氏菌的细胞内生存方式及其病原体相关分子模式,如特定的脂多糖(LPS),是其躲避和阻碍免疫系统识别的关键因素。在此,我们将综述目前关于布鲁氏菌属物种引发的逃避和免疫抑制机制的知识,这些机制使其能够在宿主中隐秘地持续存在,例如由其LPS和环状β-1,2-葡聚糖引发的机制,或涉及逃避中性粒细胞和单核细胞、损害抗原呈递、调节T细胞反应和免疫代谢的机制。还将讨论其他成功的慢性致病细菌(包括结核分枝杆菌、麻风分枝杆菌和幽门螺杆菌)所采用的有吸引力的策略,特别强调布鲁氏菌病中起作用的机制,如肉芽肿形成、细胞焦亡以及对I型和III型干扰素、B细胞、固有淋巴细胞和宿主脂质的操纵。更好地理解这些策略对于对抗细菌慢性感染以及设计创新的治疗方法和疫苗至关重要。